Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells

• Masashi Kumon ,

  Contributed equally to this work with: Masashi Kumon, Masahiro Fuwa

  Roles Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing

  Affiliation Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan

  ⨯
• Masahiro Fuwa ,

  Contributed equally to this work with: Masashi Kumon, Masahiro Fuwa

  Roles Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing

  * E-mail: masahiro.fuwa@santen.com

  Affiliation Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan

  https://orcid.org/0000-0002-7958-762X

  ⨯
• Atsushi Shimazaki,

  Roles Conceptualization, Writing – review & editing

  Affiliation Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan

  ⨯
• Noriko Odani-Kawabata,

  Roles Conceptualization, Writing – review & editing

  Affiliation Product Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan

  https://orcid.org/0000-0001-9776-6077

  ⨯
• Ryo Iwamura,

  Roles Writing – review & editing

  Affiliation Pharmaceutical Division, Pharmaceuticals Research Laboratory, UBE Corporation, Yamaguchi, Japan

  ⨯
• Kenji Yoneda,

  Roles Writing – review & editing

  Affiliation Pharmaceutical Division, Pharmaceuticals Research Laboratory, UBE Corporation, Yamaguchi, Japan

  ⨯
• Masatomo Kato

  Roles Conceptualization, Writing – review & editing

  Affiliation Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan

  ⨯